The mechanisms underlying the dosing time-dependent change in the antitumor
effect of interferon-beta (IFN-beta) were investigated based on the sensit
ivity of tumor cells and the pharmacokinetics of the drug. Tumor-bearing mi
ce were housed under standardized light-dark cycle conditions (lights on at
7:00 AM, off at 7:00 PM) with food and water available ad libitum. The ant
itumor effect of IFN-beta (0.5 MI.U./kg, intratumoral) was more efficient i
n early light phase than in early dark phase. The higher antitumor effect o
f IFN-beta was observed when specific binding of IFN receptor and DNA synth
esis in tumor cells increased, and the lower effect was observed when these
levels decreased. The dosing time-dependent effect of IFN-beta was support
ed by the time-dependent expression of transcription factor (signal transdu
cers and activators of transcription 1) and cell proliferation inhibitor (p
21 wild-type p53-activated fragment 1) protein induced by IFN-beta. There w
as a significant dosing time-dependent change in IFN-beta concentration in
tumor, with a higher level in early light phase and a lower level in early
dark phase. The dosing time-dependent change of IFN-beta concentration in t
umor was associated with that of IFN-beta-induced antitumor effect. These r
esults suggest that by choosing the most suitable dosing time for IFN-beta,
the efficacy of the drug can be increased in certain experimental and clin
ical situations.